LBPH - Neurology-Focused Longboard Pharmaceuticals' Stock Soars Over 200% Today - Here's Why | Benzinga
Longboard Pharmaceuticals Inc (NASDAQ: LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs).
In the study, 52 participants were enrolled to evaluate the safety, tolerability, efficacy, and pharmacokinetics of oral bexicaserin (6 mg, 9 mg, and 12 mg) three times daily (TID) versus ...